Opinion|Videos|March 25, 2025
Navigating Cost Considerations in Treatment Selection of mCRC Agents
Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key payer-related challenges (eg, step edits, prior authorizations) that impact access to third-line therapies for patients with mCRC?
- How do payer requirements influence treatment sequencing and decision-making in the third-line setting?
- How do the costs associated with adverse events across the different third-line treatments (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab) influence treatment selection?
Advertisement
Related to this article
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Across the US, Obesity Care Still Lacks an Owner
5